Single Center, Phase II Clinical Study of PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Carboplatin; Cisplatin
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 31 Jan 2025 New trial record